BTG plc is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The current name was adopted when the British Technology Group changed its name on 27 May 1998. BTG was a constituent of the FTSE 250 Index until it was acquired by Boston Scientific in August 2019.
BTG earns revenues from specialty pharmaceutical and interventional medicine product sales and on royalties from partnered products. It trades as BTG International Inc. in the United States and as BTG International Ltd. in the United Kingdom.
Traded as: LSE: BTG
Founded: 1991 as British Technology Group Ltd.
Headquarters: London, United Kingdom
Products: Development, manufacturing and commercialisation of specialty pharmaceuticals and interventional medicine in the areas of critical care, cancer and varicose veins. BTG also has a revenue stream from royalty payments on partnered products.